Close Menu

NEW YORK — British molecular assay startup Biofidelity said today that it has raised £750,000 ($906,555) in seed funding.

Investors include UK-based Longwell Ventures, as well as an undisclosed multinational diagnostics firm and private investors.

Biofidelity, founded earlier this year, is developing a technology for the detection of low-frequency genetic mutations for diagnostic applications in areas including cancer and prenatal testing.   

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.